LeMaitre Vascular, Inc. (LMAT)

In the past six months, LeMaitre Vascular reported Q2 2025 earnings per share (EPS) of $0.60, surpassing estimates, with revenue of $63.15 million, representing a 15.0% increase year-over-year, leading to increased full-year guidance. Cantor Fitzgerald raised its price objective for LMAT from $92.00 to $95.00, maintaining a "neutral" rating, while Barrington Research reiterated an "outperform" rating with a $95.00 price objective, and Weiss Ratings reiterated a "buy (b-)" rating. The company announced a quarterly dividend of $0.20, which was paid on September 4, 2025. Following its Q4 2024 earnings report on March 24, 2025, the stock was down 16.5%, despite the company beating full-year EPS guidance. There have been reports of significant insider selling, particularly by the Chairman & CEO. On October 27, 2025, the stock price gained 1.02%, rising from $89.21 to $90.12.

LeMaitre Vascular experiences demand seasonality for its products and services. The third quarter (Q3) typically tends to be one of the company's lower quarters, primarily due to the impact of the European summer on revenue. Additionally, operating expenses are generally lower in the second half of the year, influenced by seasonality related to variable compensation.

LeMaitre Vascular, Inc. is a medical device company specializing in products for the treatment of peripheral vascular disease. The company develops, manufactures, and markets medical devices, implants, and services for vascular surgeons for open vascular surgery and minimally invasive procedures. The company's sector is Healthcare, specifically within the Medical Equipment and Specialized Medical Devices industry. Major products include biologic and synthetic grafts, embolectomy and thrombectomy catheters, valvulotomes, carotid shunts, and human tissue cryopreservation services.

LeMaitre Vascular has a significant global presence, selling directly to hospitals in 31 countries and utilizing a network of distributors to reach over 70 countries across North America, Europe, and the Asia/Pacific Rim. The company has direct offices and distributors in numerous countries worldwide, including in Europe, Asia, and the Americas.

LeMaitre Vascular generally maintains a positive brand reputation within the medical device industry. The company is recognized as a leading global innovator, manufacturer and marketer of devices, implants and services for the treatment of peripheral vascular disease. Analysts have a Moderate Buy consensus rating for the stock, with an average target price of $97.60. The company emphasizes its commitment to innovation and a focus on customer satisfaction, employee well-being, and stockholder value. While there have been reports of insider selling, particularly by the Chairman & CEO, it has not been widely reported as a major reputation-damaging event.

LeMaitre Vascular's ownership is distributed among institutional investors, individual insiders, and retail investors. Institutional investors hold a substantial portion of the company's stock, ranging from approximately 58.45% to 83.93%, while individual insiders hold around 7.23% to 7.89% of the shares. Major institutional owners include BlackRock, Inc., Conestoga Capital Advisors, LLC, and Vanguard Group Inc.